Monopar Therapeutics

General Information
Business:

We are a clinical stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. We are building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. We leverage our scientific and clinical experience to help de-risk and accelerate the clinical development of our drug product candidates. We intend to begin a Phase 3 clinical development program for our lead product candidate, Validive (clonidine mucobuccal tablet; clonidine MBT), in the fourth quarter of 2019.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 5
Founded: 2014
Contact Information
Address 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091, US
Phone Number (847) 388-0349
Web Address http://www.monopartx.com
View Prospectus: Monopar Therapeutics
Financial Information
Market Cap $267.4mil
Revenues $0 mil (last 12 months)
Net Income $-3.8 mil (last 12 months)
IPO Profile
Symbol MNPR
Exchange NASDAQ
Shares (millions): 4.4
Price range $8.00 - $10.00
Est. $ Volume $40.0 mil
Manager / Joint Managers JonesTrading
CO-Managers -
Expected To Trade: 10/1/2019
Day: Tuesday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change